Vaccines against malaria

Clinical Infectious Diseases

Volumn 60, Issue 6, 2015, Pages 930-936

  Ouattara, Amed ^a   Laurens, Matthew B ^b  

^a Center for Vaccine Development   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Malaria; P. falciparum; P. vivax; Vaccine

Indexed keywords

MALARIA VACCINE; ANTIMALARIAL AGENT; PARASITE ANTIGEN;

APICOMPLEXAN LIFE CYCLE STAGE; ARTICLE; ERYTHROCYTE; GENETIC VARIABILITY; HUMAN; IMMUNE RESPONSE; MALARIA; NONHUMAN; PARASITE TRANSMISSION; PLASMODIUM; PREGNANCY; PRIORITY JOURNAL; FEMALE; GROWTH, DEVELOPMENT AND AGING; IMMUNOLOGY; MALARIA, FALCIPARUM; MEDICAL RESEARCH; PARASITOLOGY; PLASMODIUM FALCIPARUM; PREGNANCY COMPLICATIONS, PARASITIC;

ANTIGENS, PROTOZOAN; ANTIMALARIALS; BIOMEDICAL RESEARCH; FEMALE; GENETIC VARIATION; HUMANS; MALARIA; MALARIA VACCINES; MALARIA, FALCIPARUM; PLASMODIUM FALCIPARUM; PREGNANCY; PREGNANCY COMPLICATIONS, PARASITIC;

EID: 84936098948     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu954     Document Type: Article

References (43)

1. World Health Organization. World Malaria Report: 2013. Geneva, Switzerland, World Health Organization.
2. Malaria Vaccine Technology Roadmap. Malaria Vaccine Funders Group. World Health Organization, 2013. Available at: http://www. who.int/immunization/topics/malaria/vaccine-roadmap/en/.
3. Schwartz L, Brown GV, Genton B, Moorthy VS. A review of malaria vaccine clinical projects based on the WHO rainbow table. Malar J 2012; 11:11.
4. Freund J, Thomson KJ, Sommer HE,Walter AW, Schenkein EL. Immunization of rhesus monkeys against malarial infection (P. knowlesi) with killed parasites and adjuvants. Science 1945; 102:202-4.
5. Clyde DF, Most H, McCarthy VC, Vanderberg JP. Immunization of man against sporozite-induced falciparum malaria. Am J Med Sci 1973; 266:169-77.
6. Laurens MB, Roestenberg M, Moorthy VS. A consultation on the optimization of controlled human malaria infection by mosquito bite for evaluation of candidate malaria vaccines. Vaccine 2012; 30:5302-4.
7. Kester KE, Cummings JF, Ofori-Anyinam O, et al. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. J Infect Dis 2009; 200:337-46.
8. Clyde DF. Immunization of man against falciparum and vivax malaria by use of attenuated sporozoites. Am J Trop Med Hyg 1975; 24:397-401.
9. Graves P, Gelband H. Vaccines for preventing malaria (blood-stage). Cochrane Database Syst Rev 2006:CD006199.
10. Greenwood B, Targett G. Do we still need a malaria vaccine? Parasite Immunol 2009; 31:582-6.
11. Agnandji ST, Lell B, Fernandes JF, et al. A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N Engl J Med 2012; 367:2284-95.
12. Mackintosh CL, Beeson JG, Marsh K. Clinical features and pathogenesis of severe malaria. Trends Parasitol 2004; 20:597-603.
13. Miller LH, Baruch DI, Marsh K, Doumbo OK. The pathogenic basis of malaria. Nature 2002; 415:673-9.
14. Iriemenam NC, Khirelsied AH, Nasr A, et al. Antibody responses to a panel of Plasmodium falciparum malaria blood-stage antigens in relation to clinical disease outcome in Sudan. Vaccine 2009; 27:62-71.
15. Iriemenam NC, Okafor CM, Balogun HA, et al. Cytokine profiles and antibody responses to Plasmodium falciparum malaria infection in individuals living in Ibadan, southwest Nigeria. Afr Health Sci 2009; 9:66-74.
16. McCall MB, Roestenberg M, Ploemen I, et al. Memory-like IFN-gamma response by NK cells following malaria infection reveals the crucial role of T cells in NK cell activation by P. falciparum. Eur J Immunol 2010; 40:3472-7.
17. Kappe SH, Buscaglia CA, Nussenzweig V. Plasmodium sporozoite molecular cell biology. Annu Rev Cell Dev Biol 2004; 20:29-59.
18. Dame JB,Williams JL, McCutchan TF, et al. Structure of the gene encoding the immunodominant surface antigen on the sporozoite of the human malaria parasite Plasmodium falciparum. Science 1984; 225:593-9.
19. Potocnjak P, Yoshida N, Nussenzweig RS, Nussenzweig V. Monovalent fragments (Fab) of monoclonal antibodies to a sporozoite surface antigen (Pb44) protect mice against malarial infection. J Exp Med 1980; 151:1504-13.
20. Agnandji ST, Lell B, Fernandes JF, et al. Efficacy and safety of the RTS,S/ AS01 malaria vaccine during 18 months after vaccination: A phase 3 randomized, controlled trial in children and young infants at 11 African sites. PLoS Med 2014; 11:e1001685.
21. Heppner DG Jr, Kester KE, Ockenhouse CF, et al. Towards an RTS,Sbased, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research. Vaccine 2005; 23:2243-50.
22. Dunachie SJ,Walther M, Vuola JM, et al. A clinical trial of prime-boost immunisation with the candidate malaria vaccines RTS,S/AS02A and MVA-CS. Vaccine 2006; 24:2850-9.
23. Alloueche A, Milligan P, Conway DJ, et al. Protective efficacy of the RTS,S/AS02 Plasmodium falciparum malaria vaccine is not strain specific. Am J Trop Med Hyg 2003; 68:97-101.
24. Enosse S, Dobano C, Quelhas D, et al. RTS,S/AS02A malaria vaccine does not induce parasite CSP T cell epitope selection and reduces multiplicity of infection. PLoS Clin Trials 2006; 1:e5.
25. Waitumbi JN, Anyona SB, Hunja CW, et al. Impact of RTS,S/AS02(A) and RTS,S/AS01(B) on genotypes of P. falciparum in adults participating in a malaria vaccine clinical trial. PLoS One 2009; 4:e7849.
26. Ouattara A, Takala-Harrison S, Thera MA, et al. Molecular basis of allele-specific efficacy of a blood-stage malaria vaccine: vaccine development implications. J Infect Dis 2013; 207:511-9.
27. Gandhi K, Thera MA, Coulibaly D, et al. Next generation sequencing to detect variation in the Plasmodium falciparum circumsporozoite protein. Am J Trop Med Hyg 2012; 86:775-81.
28. Bejon P, Ogada E, Mwangi T, et al. Extended follow-up following a phase 2b randomized trial of the candidate malaria vaccines FP9 METRAP and MVA ME-TRAP among children in Kenya. PLoS One 2007; 2:e707.
29. Ewer KJ, O'Hara GA, Duncan CJ, et al. Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation. Nat Commun 2013; 4:2836.
30. Seder RA, Chang LJ, Enama ME, et al. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science 2013; 341:1359-65.
31. Sabchareon A, Burnouf T, Ouattara D, et al. Parasitologic and clinical human response to immunoglobulin administration in falciparum malaria. Am J Trop Med Hyg 1991; 45:297-308.
32. Cohen S, McGregor IA, Carrington S. Gamma-globulin and acquired immunity to human malaria. Nature 1961; 192:733-7.
33. Polley SD, Tetteh KK, Lloyd JM, et al. Plasmodium falciparum merozoite surface protein 3 is a target of allele-specific immunity and alleles are maintained by natural selection. J Infect Dis 2007; 195: 279-87.
34. Genton B, Betuela I, Felger I, et al. A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea. J Infect Dis 2002; 185:820-7.
35. Thera MA, Doumbo OK, Coulibaly D, et al. A field trial to assess a blood-stage malaria vaccine. N Engl J Med 2011; 365:1004-13.
36. Matuschewski K, Mueller AK. Vaccines against malaria-an update. FEBS J 2007; 274:4680-7.
37. Malkin EM, Durbin AP, Diemert DJ, et al. Phase 1 vaccine trial of Pvs25H: A transmission blocking vaccine for Plasmodium vivax malaria. Vaccine 2005; 23:3131-8.
38. Wu Y, Ellis RD, Shaffer D, et al. Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51. PLoS One 2008; 3:e2636.
39. Da DF, Dixit S, Sattabonkot J, et al. Anti-Pfs25 human plasma reduces transmission of Plasmodium falciparum isolates that have diverse genetic backgrounds. Infect Immun 2013; 81:1984-9.
40. Niederwieser I, Felger I, Beck HP. Limited polymorphism in Plasmodium falciparum sexual-stage antigens. Am J Trop Med Hyg 2001; 64:9-11.
41. Salanti A, Dahlback M, Turner L, et al. Evidence for the involvement of VAR2CSA in pregnancy-associated malaria. J Exp Med 2004; 200: 1197-203.
42. Srivastava A, Durocher Y, Gamain B. Expressing full-length functional PfEMP1 proteins in the HEK293 expression system. Methods Mol Biol 2013; 923:307-19.
43. A research agenda for malaria eradication: vaccines. PLoS Med 2011; 8: e1000398.